Metabolic basis of drug interactions in the intensive care unit

Critical Care Nursing Quarterly

Volumn 22, Issue 4, 2000, Pages 1-13

  Streetman, Daniel S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cytochrome P450; Drug interactions; Drug metabolism; Intensive care unit

Indexed keywords

ALUMINUM HYDROXIDE; AMIODARONE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIPROFLOXACIN; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450; DAPSONE; DICLOFENAC; ENZYME; ERYTHROMYCIN; LANSOPRAZOLE; LORAZEPAM; MAGNESIUM HYDROXIDE; MIBEFRADIL; MORPHINE; NEUROLEPTIC AGENT; PHENYTOIN; RITONAVIR; STEROID; TACROLIMUS; TERFENADINE; UNINDEXED DRUG;

CONSTIPATION; CRITICAL ILLNESS; DIARRHEA; DRUG METABOLISM; GENETICS; HUMAN; INTENSIVE CARE UNIT; NUTRITION; RESPIRATION DEPRESSION; REVIEW; TORSADE DES POINTES;

EID: 0033980268     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200002000-00002     Document Type: Review

References (29)

1. Stockley IH. General considerations and an outline survey of some basic interaction mechanisms. In: Drug Interactions. 3rd ed. Cambridge, MA: Blackwell Scientific Publications; 1994;1-14.
2. Hansten PD, Horn JR. Drug Interactions Analysis and Management. St. Louis, MO: Facts and Comparisons; 1999.
3. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm. 1996;24:449-459.
4. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am. 1992;21:511-526.
5. Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26:144-160.
6. Gibson GG, Skett P. Pathways of drug metabolism. In: Introduction to Drug Metabolism. New York: Chapman & Hall; 1986;1-38.
7. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361-390.
8. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit. 1998;20:517-524.
9. Michalets EL. Update: Clinically-significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
10. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29:413-580.
11. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: Evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology. 1994;19:1141-1148.
12. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641-649.
13. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol. 1996;51:289-295.
14. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. Tarrytown, NY: Pergamon; 1992;625-648.
15. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 1996;31:47-64.
16. Gibson GG, Skett P. Factors affecting drug metabolism: External factors. In: Introduction to Drug Metabolism. New York: Chapman & Hall; 1986;147-174.
17. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr. 1995;61(suppl):651S-658S.
18. Hong J, Pan J, Gonzalez FJ, Gelboin HV, Yang CS. The induction of a specific form of cytochrome P450 (P450j) by fasting. Biochem Biophys Res Commun. 1987;142:1077-1083.
19. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol. 1998;12:553-558.
20. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther. 1994;56:359-367.
21. DiPiro JT, Hooker KD, Sherman JC, Gaines MG, Wynn JJ. Effect of experimental hemorrhagic shock on hepatic drug elimination. Crit Care Med. 1992;20:810-815.
22. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth. 1996;77:32-49.
23. Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet. 1998;35:293-312.
24. Wilkinson GR, Branch RA. Effects of hepatic disease on clinical pharmacokinetics. In: Benet LZ, Massoud N, Gambertoglio JG, eds. Pharmacokinetic Basis for Drug Treatment. New York: Raven Press; 1984.
25. Keiding S. Drug administration to liver patients: Aspects of liver pathophysiology. Semin Liver Dis. 1995;15:268-282.
26. Touchette MA, Slaughter RA. The effect of renal failure on hepatic drug clearance. DICP Ann Pharmacother. 1991;25:1214-1224.
27. McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy. 1998; 18:759-778.
28. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995;5:259-274.
29. Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res. 1998;400:201-213.